Dermatomyositis Market, By Type, By Treatment Type, By Distribution Channel, By Geography

Description

Dermatomyositis Market is estimated to be valued at USD 637.7 Mn in 2026 and is expected to reach USD 931.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.5% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 637.7 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	5.50%	2033 Value Projection:	USD 931.6 Mn

Dermatomyositis is a rare condition that causes muscle inflammation. It presents with symmetric proximal muscle weakness, skin rash, and extra macular manifestations such as esophageal dysfunction and interstitial lung disease. Dermatomyositis is strongly associated with malignancy, especially in adults. Dermatomyositis is a systemic disorder that most frequently affects the skin and muscles but may also affect the joints, the esophagus, the lungs, and less commonly, the heart. Dermatomyositis presents with characteristic skin findings and symmetric proximal skeletal muscle weakness. It can also affect other organ systems such as the pulmonary, cardiovascular, and gastrointestinal systems. Various factors cause dermatomyositis such as genetic factors, immunologic factors, and environmental factors such as infections, drugs, and radiation.

Furthermore, there are three types of dermatomyositis namely, Adult Dermatomyositis, Dermatomyositis Sine Myositis, and Juvenile (Childhood) Dermatomyositis (JDMS). Dermatomyositis Sine Myositis is a term used to describe patients who are present with the dermatological features of dermatomyositis but an absence of associated muscle findings. Juvenile (childhood) dermatomyositis (JDMS) is an early onset form of dermatomyositis (DM), a systemic, autoimmune inflammatory muscle disorder with vasculopathy, characterized by proximal and symmetrical muscle weakness, evocative skin lesions, and systemic manifestations.

Market Dynamics

Market players are involved in the development of novel treatment for dermatomyositis which is expected to propel the market growth over the forecast period. For instance, in May 2022, Kezar Life Sciences, Inc., a clinical-stage biotechnology company, announced result from the PRESIDIO Phase 2 clinical trial of zetomipzomib (KZR-616) in patients with dermatomyositis (DM) and polymyositis (PM). The results of the PRESIDIO trial showed that most DM and PM patients saw clinically meaningful improvements in total improvement score (TIS).

Key features of the study

This report provides an in-depth analysis of the global dermatomyositis market, market size (USD Mn), and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dermatomyositis market based on the following parameters - company highlights, types portfolio, key highlights, financial performance, and market strategies
Key companies covered as a part of this study include AstraZeneca Plc., Bristol-Myers Squibb Company, Octapharma AG, Corbus Pharmaceuticals Holdings, Inc., CSL Limited, Ermium Therapeutics, Kezar Life Sciences Inc., Mallinckrodt Plc., Neovacs, Horizon Therapeutics plc., and Pfizer Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global dermatomyositis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatomyositis market

Dermatomyositis Market Segmentation

By Type (Revenue, USD Mn, 2020 - 2033)
- Adult Dermatomyositis
- Dermatomyositis Sine Myositis
- Juvenile (Childhood) Dermatomyositis (JDMS)
By Treatment Type Insights (Revenue, USD Mn, 2020 - 2033)
- Anti-inflammatory Medication
- Immunosuppressive Drugs
- Immunoglobulin
- Others (Plasma Exchange, Monoclonal antibody among others)
By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region Insights (Revenue, USD Mn, 2020 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
Key Players
- AstraZeneca Plc.
- Bristol-Myers Squibb Company
- Octapharma AG
- Corbus Pharmaceuticals Holdings, Inc.
- CSL Limited
- Ermium Therapeutics
- Kezar Life Sciences Inc.
- Mallinckrodt Plc.
- Neovacs, Horizon Therapeutics plc.
- Pfizer Inc.

Product Code: CMI5250

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Treatment Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Market Opportunity Map

3. Global Dermatomyositis Market Insights

Drivers
Restraints
Opportunity
Impact Analysis
Pipeline Analysis
PEST Analysis
Porter's Five Forces Analysis
Key Developments
Regulatory Scenario
Reimbursement Scenario
Merger & Acquisition Scenario
Brand Mapping

4. Global Dermatomyositis Market, By Type, 2026 - 2033 (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Adult Dermatomyositis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
Dermatomyositis Sine Myositis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
Juvenile (Childhood) Dermatomyositis (JDMS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)

5. Global Dermatomyositis Market, By Treatment Type, 2026 - 2033 (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Anti-inflammatory Medication
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
Immunosuppressive Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
Immunoglobulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
Others (Plasma Exchange, Monoclonal antibody among others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)

6. Global Dermatomyositis Market, By Distribution Channel, 2026 - 2033 (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033 (USD Mn)

7. Global Dermatomyositis Market, By Region, 2026 - 2033 (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Region at Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (USD Mn)
- Market Size and Forecast by Value, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (USD Mn)
- Market Size and Forecast by Value, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (USD Mn)
- Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (USD Mn)
- Market Size and Forecast by Value, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (USD Mn)
- Market Size and Forecast by Value, and Y-o-Y Growth, By Country, 2020-2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030, (USD Mn)
- Market Size and Forecast by Value, and Y-o-Y Growth, By Country/Region, 2020-2033, (USD Mn)
  - South Africa
  - Central Africa
  - North Africa

8. Company Profiles

AstraZeneca Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Octapharma AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Corbus Pharmaceuticals Holdings, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
CSL Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Ermium Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Kezar Life Sciences Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Mallinckrodt Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Neovacs
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Horizon Therapeutics plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies

9. Section

Research Methodology
About us